NASDAQ: ODTX
Odyssey Therapeutics Inc Stock Forecast, Predictions & Price Target

Analyst price target for ODTX

Based on 7 analysts offering 12 month price targets for Odyssey Therapeutics Inc

Min Forecast
$27.00+35%
Avg Forecast
$36.00+80%
Max Forecast
$44.00+120%

Should I buy or sell ODTX stock?

Based on 9 analysts offering ratings for Odyssey Therapeutics Inc.

Strong Buy
Strong Buy
4 analysts 44.44%
Buy
5 analysts 55.56%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although ODTX's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates ODTX as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -6.47% per year. Learn More

Be the first to know when Wall Street analysts revise their ODTX stock forecasts and price targets.

ODTX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-11-06
lockedlocked$00.00+00.00%2026-10-12
lockedlocked$00.00+00.00%2026-10-09
lockedlocked$00.00+00.00%2026-08-27
lockedlocked$00.00+00.00%2026-08-07
Oppenheimer
Top 10%
91
BuyReiterates$40.00+100.00%2026-06-18
Cantor Fitzgerald
Top 4%
97
Strong BuyInitiates Coverage OnN/AN/A2026-06-02
TD Cowen
Top 32%
69
Strong BuyInitiates Coverage OnN/AN/A2026-06-02
Wedbush
Top 5%
96
BuyInitiates Coverage On$30.00+50.00%2026-06-02

1 of 1

Forecast return on equity

Is ODTX forecast to generate an efficient return?

Company
-46.45%
Industry
18.06%
Market
161.1%
ODTX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ODTX forecast to generate an efficient return on assets?

Company
-39.84%
Industry
19.62%
ODTX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ODTX earnings per share forecast

What is ODTX's earnings per share in the next 3 years based on estimates from 9 analysts?

Avg 1 year Forecast
-$6.18
Avg 2 year Forecast
-$4.82
Avg 3 year Forecast
-$4.38

ODTX revenue forecast

What is ODTX's revenue in the next 3 years based on estimates from 9 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

ODTX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ODTX$20.00$36.00+80.00%Strong Buy
CRVS$11.37N/AN/A
AKTS$17.45$36.67+110.13%Strong Buy
PHAR$13.22$39.00+195.01%Strong Buy
SLN$19.79$26.00+31.38%Buy

Odyssey Therapeutics Stock Forecast FAQ

Is Odyssey Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 9 Wall Street analysts covering (NASDAQ: ODTX) stock is to Strong Buy ODTX stock.

Out of 9 analysts, 4 (44.44%) are recommending ODTX as a Strong Buy, 5 (55.56%) are recommending ODTX as a Buy, 0 (0%) are recommending ODTX as a Hold, 0 (0%) are recommending ODTX as a Sell, and 0 (0%) are recommending ODTX as a Strong Sell.

If you're new to stock investing, here's how to buy Odyssey Therapeutics stock.

What is ODTX's earnings growth forecast for 2026-2028?

(NASDAQ: ODTX) Odyssey Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.6%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.59%.

Odyssey Therapeutics's earnings in 2026 is N/A.On average, 9 Wall Street analysts forecast ODTX's earnings for 2026 to be -$297,045,059, with the lowest ODTX earnings forecast at -$344,819,722, and the highest ODTX earnings forecast at -$275,068,426. On average, 10 Wall Street analysts forecast ODTX's earnings for 2027 to be -$231,480,475, with the lowest ODTX earnings forecast at -$331,629,897, and the highest ODTX earnings forecast at -$177,658,873.

In 2028, ODTX is forecast to generate -$210,397,904 in earnings, with the lowest earnings forecast at -$270,391,422 and the highest earnings forecast at -$141,824,271.

What is ODTX's revenue growth forecast for 2026-2028?

(NASDAQ: ODTX) Odyssey Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 28.18%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.17%.

Odyssey Therapeutics's revenue in 2026 is N/A.On average, 9 Wall Street analysts forecast ODTX's revenue for 2026 to be $0, with the lowest ODTX revenue forecast at $0, and the highest ODTX revenue forecast at $0. On average, 9 Wall Street analysts forecast ODTX's revenue for 2027 to be $0, with the lowest ODTX revenue forecast at $0, and the highest ODTX revenue forecast at $0.

In 2028, ODTX is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is ODTX's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: ODTX) forecast ROA is -39.84%, which is lower than the forecast US Biotechnology industry average of 19.62%.

What is ODTX's Price Target?

According to 7 Wall Street analysts that have issued a 1 year ODTX price target, the average ODTX price target is $36.00, with the highest ODTX stock price forecast at $44.00 and the lowest ODTX stock price forecast at $27.00.

On average, Wall Street analysts predict that Odyssey Therapeutics's share price could reach $36.00 by Nov 6, 2027. The average Odyssey Therapeutics stock price prediction forecasts a potential upside of 80% from the current ODTX share price of $20.00.

What is ODTX's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: ODTX) Odyssey Therapeutics's current Earnings Per Share (EPS) is N/A. On average, analysts forecast that ODTX's EPS will be -$6.18 for 2026, with the lowest EPS forecast at -$7.17, and the highest EPS forecast at -$5.72. On average, analysts forecast that ODTX's EPS will be -$4.82 for 2027, with the lowest EPS forecast at -$6.90, and the highest EPS forecast at -$3.70. In 2028, ODTX's EPS is forecast to hit -$4.38 (min: -$5.63, max: -$2.95).

What is ODTX's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: ODTX) forecast ROE is -46.45%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.